TC BioPharm aims to slash cancer treatment costs

EDINBURGH - TC BioPharm (Holdings) PLC (NASDAQ: TCBP), a clinical stage biotechnology company, announced today its plans to significantly reduce the cost of its cancer treatments by developing a more efficient manufacturing process. The company, which specializes in allogeneic gamma-delta T cell therapies, intends to use its existing infrastructure to expand its treatment capacity from 52 to over 1,000 patient treatments annually.

This move is expected to result in an 85% reduction in cost per patient treatment. The implementation of this new manufacturing process at their current facility is scheduled to take place within the next 24 months.

Dr. Lauren Bor, Ph.D., Senior Manager of Process Development and Commercialization at TC BioPharm, stated, "This enterprise is necessary to address the challenging operating landscape in cell therapy and better position TC BioPharm both economically and operationally." Dr. Bor emphasized the importance of this development in maintaining the company's leadership position and preparing for a broader commercialization strategy.

The company's innovation in manufacturing is part of its strategy to improve patient outcomes while also creating value for shareholders. By addressing the high costs of cell therapy manufacturing, TC BioPharm aims to make treatments more accessible and maintain a competitive edge in the market.

The information regarding these developments is based on a press release statement from TC BioPharm. It should be noted that forward-looking statements involve risks and uncertainties, and there are no guarantees that the anticipated cost savings or manufacturing capacity increases will be achieved.

TC BioPharm is recognized for its pioneering work in gamma-delta T cell therapies and is the first company to conduct phase II/pivotal clinical studies in oncology with its product line. Their proprietary CryoTC technology allows for the global distribution of their frozen cell therapy products, targeting diseases such as acute myeloid leukemia.

As TC BioPharm (Holdings) PLC (NASDAQ: TCBP) forges ahead with its ambitious plans to revolutionize cancer treatment affordability, the company's financial metrics and market performance provide a backdrop to these initiatives. With a market capitalization of just 1.48 million USD, TC BioPharm is a relatively small player in the biotechnology industry. Despite the company's innovative approach to cell therapy, its stock has experienced significant volatility, as reflected by a 1-week price total return of -10.56% and a staggering 1-year price total return of -96.03%. These figures underscore the challenges TC BioPharm faces in the market.

Moreover, the company's revenue growth over the last twelve months as of Q2 2023 stands at 44.3%, indicating a robust increase despite the company not being profitable over the same period. An InvestingPro Tip highlights that analysts anticipate a sales decline in the current year, which could be a concern for investors looking at long-term growth prospects. Additionally, TC BioPharm does not pay a dividend, suggesting that investors are likely relying on stock price appreciation for returns, which has been underwhelming in recent times, as evidenced by the significant price drop over the last three months (-59.42%).

Get The App

Join the millions of people who stay on top of global financial markets with Investing.com.

Download Now

For those considering an investment in TC BioPharm, it could be valuable to explore the 12 additional InvestingPro Tips available on the platform, which provide deeper insights into the company's financial health and stock performance. Interested investors can uncover these tips by visiting https://www.investing.com/pro/TCBP and can take advantage of an additional 10% off a yearly or biyearly Pro and Pro+ subscription with the coupon code PRONEWS24.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.